Home - Gilde Healthcare

Enabling
better care
at lower cost

One firm with two strategies
Gilde Healthcare is a specialized healthcare investor with over €2.6bn under management across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare is headquartered in Utrecht, the Netherlands with local offices in Frankfurt, Germany and Boston, US.

Utrecht, The Netherlands
Frankfurt am Main, Germany
Boston, United States of America

Venture&Growth

About Venture&Growth

Private Equity

About Private Equity

Investment philosophy

Gilde Healthcare invests in businesses enabling better care at lower cost.
40
years in business

Venture&Growth

Gilde Healthcare Venture&Growth invests in healthtech and therapeutics. The Venture&Growth fund supports fast growing companies in Europe and North America.
69
Venture&Growth companies in portfolio
under management
2.6B

Private Equity

Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to the healthcare sector.
24
Private Equity companies in portfolio
40
years in business
69
Venture&Growth companies in portfolio
under management
2.6B
24
Private Equity companies in portfolio

Team

Our transatlantic team, comprising sector specialists with operating and financial backgrounds leverages its deep industry knowledge to achieve outsized returns on companies that deliver better care at lower costs.

Portfolio

Gilde Healthcare invests in firms that support the healthcare sector such as healthcare providers, medical product suppliers, and service providers, as well as disruptive companies active in medtech, digital health, medical instruments, and therapeutics.

Responsible Investment at Gilde Healthcare:

We focus on both ESG and Impact: ESG sets the foundation with responsible practices, while Impact drives measurable change in healthcare. Check out our impact cases to see how we’re making a difference.

Read more about ESG/impact

News

Keep up to date with Gilde Healthcare announcements and portfolio company news.

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...

10 September 2025